Form D · Biotechnology
Synlico Inc.
South San Francisco, CA · CIK 0001880583
Offering snapshot reported Feb 25, 2025 · SEC filing
- Reported sold
- $3M Offering amount: $3M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 24, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 25, 2025 | Initial | $3,000,000 | No comparison | 1 | SEC filing |
| Mar 28, 2023 | Amendment | $240,000 | $0vs Mar 20, 2023 | 1 | SEC filing |
| Mar 20, 2023 | Initial | $240,000 | No comparison | 1 | SEC filing |
| Aug 27, 2021 | Initial | $2,000,040 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-539116
Convertible Note
Source: Form D, filed Feb 25, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jingwei Lu | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
329 Oyster Point Blvd Fl 3
South San Francisco, CA, 94080
South San Francisco, CA, 94080